It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Detecting ligand-protein interactions in living cells is a fundamental challenge in molecular biology and drug research. Proteome-wide profiling of thermal stability as a function of ligand concentration promises to tackle this challenge. However, current data analysis strategies use preset thresholds that can lead to suboptimal sensitivity/specificity tradeoffs and limited comparability across datasets. Here, we present a method based on statistical hypothesis testing on curves, which provides control of the false discovery rate. We apply it to several datasets probing epigenetic drugs and a metabolite. This leads us to detect off-target drug engagement, including the finding that the HDAC8 inhibitor PCI-34051 and its analog BRD-3811 bind to and inhibit leucine aminopeptidase 3. An implementation is available as an R package from Bioconductor (https://bioconductor.org/packages/TPP2D). We hope that our method will facilitate prioritizing targets from thermal profiling experiments.
2D-thermal proteome profiling (2D-TPP) is a powerful assay for probing interactions of proteins with small molecules in their native context. Here the authors provide a statistical method for false discovery rate controlled analysis for 2D-TPP applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Becher, Isabelle 2
; Sridharan Sindhuja 3
; Franken Holger 4 ; Mateus André 2
; Simon, Anders 5
; Bantscheff Marcus 4
; Huber, Wolfgang 2
; Savitski, Mikhail M 2
1 Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X); Heidelberg University, Faculty of Biosciences, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
2 Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X)
3 Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X); GlaxoSmithKline, Cellzome GmbH, Heidelberg, Germany (GRID:grid.420105.2) (ISNI:0000 0004 0609 8483)
4 GlaxoSmithKline, Cellzome GmbH, Heidelberg, Germany (GRID:grid.420105.2) (ISNI:0000 0004 0609 8483)
5 Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)




